EUVIMEDEUVIMED entdecken
Open Access

Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein

Yingcai Xiong iD, Keyu Tao, Tao Li, Yinghui Zhou, Zhaowei Zhang, Weiying Ou, Zhao Wang, Shouchuan Wang, Yayi Hou, Peng Cao iD, Jianjian Ji iD

Journal of Virology · 2024

DOI: 10.1128/jvi.01536-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2024. Verfasst von Yingcai Xiong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Children's Health and Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Hydrolyzable Tannins, Virus Internalization, Antiviral Agents, Viral Fusion Proteins. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | National Natural Science Foundation of China (NSFC), Young Elite scientists sponsorship Program by CACM.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections, with no currently available small-molecule drugs that are both safe and effective. A major obstacle in antiviral drug development is the rapid emergence of drug-resistant viral strains. Targeting multiple viral compounds may help mitigate the development of resistance. Herein, we conducted a drug screening using the Antiviral Traditional Chinese Medicine Active Compound Library, aiming to identify compounds that simultaneously target the RSV fusion (F) protein, glycoprotein (G), and the host heparan sulfate proteoglycans (HSPGs). From this screening, 10 candidate compounds were identified for their ability to interact with all three targets. Among these 10 candidates, chebulagic acid (CHLA) and punicalagin (PUG) demonstrated the most potent inhibition of RSV replication. In vitro dose–response assays confirmed the antiviral efficacy of CHLA (IC50: 0.07864 µM) and PUG (IC50: 0.08065 µM). Further experiments revealed both CHLA and PUG disrupt RSV attachment and membrane fusion by targeting the RSV-F and G proteins, rather than HSPG. Notably, CHLA and PUG were found to bind to the CX3C motif of the RSV-G protein, with docking assays predicting their binding sites at cysteines 176 and 182. Additionally, CHLA enhanced the conformational stability of the RSV-F protein before fusion. In an in vivo study, both CHLA and PUG were shown to alleviate RSV-induced pulmonary pathology by reducing viral titers, mitigating lung injury, and suppressing the inflammatory responses in the lungs. Our findings suggest that CHLA and PUG hold potential as therapeutic agents for RSV infection. IMPORTANCE A significant challenge in developing anti-respiratory syncytial virus (RSV) agents is the rapid emergence of resistant viral strains. Designing drugs that target multiple viral components can effectively reduce the likelihood of developing resistant strains. In this study, we screened compounds from the Antiviral Traditional Chinese Medicine Active Compound Library, aiming to simultaneously targe the RSV fusion (F) protein, glycoprotein (G), and host heparan sulfate proteoglycans (HSPGs). Our findings revealed that chebulagic acid (CHLA) and punicalagin (PUG) significantly inhibited RSV replication both in vitro and in vivo and interacted with all three targets. Both CHLA and PUG were able to disrupt RSV attachment and membrane fusion. Mechanistically, CHLA and PUG were found to bind to the CX3C motif of the RSV-G protein, with CHLA also enhancing the conformational stability of the RSV-F protein before fusion. In conclusion, our study suggests that CHLA and PUG hold promise as therapeutic agents against RSV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydrolyzable TanninsVirus InternalizationAntiviral AgentsViral Fusion ProteinsRespiratory Syncytial Virus InfectionsVirus ReplicationHumansAnimalsMiceGlycoproteinsRespiratory Syncytial Virus, HumanCell LineHeparan Sulfate ProteoglycansBenzopyransGlucosides

Stichwörter der Autor:innen

chebulagic acidfusion proteinglycoproteinpunicalaginrespiratory syncytial virus

Substanzen

Hydrolyzable TanninsAntiviral AgentspunicalaginViral Fusion Proteinschebulagic acidGlycoproteinsHeparan Sulfate ProteoglycansBenzopyransGlucosides

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Children's Health and Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • School of Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
  • The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Medical School, Nanjing University, Nanjing, China.
  • State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture, Nanjing University of Chinese Medicine, Nanjing, China.
  • Jiangsu Provincial Medical Innovation Center, Afliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.

ORCID-Profile: Yingcai Xiong, Peng Cao, Jianjian Ji

Förderung

  • MOST | National Key Research and Development Program of China (NKPs)
  • MOST | National Natural Science Foundation of China (NSFC)
  • Young Elite scientists sponsorship Program by CACM
  • | Natural Science Research of Jiangsu Higher Education Institutions of China (Natural Science Foundation of Colleges and Universities in Jiangsu Province)
  • 江苏省教育厅 | Natural Science Research of Jiangsu Higher Education Institutions of China

Zitieren

APA

Xiong, Y., Tao, K., Li, T., Zhou, Y., Zhang, Z., Ou, W., Wang, Z., Wang, S., Hou, Y., Cao, P., & Ji, J. (2024). Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein. Journal of Virology. https://doi.org/10.1128/jvi.01536-24

Vancouver

Xiong Y, Tao K, Li T, Zhou Y, Zhang Z, Ou W, et al. Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein. Journal of Virology. 2024. doi:10.1128/jvi.01536-24

BibTeX
@article{Xiong2024,
  author = {Xiong, Yingcai and Tao, Keyu and Li, Tao and Zhou, Yinghui and Zhang, Zhaowei and Ou, Weiying and Wang, Zhao and Wang, Shouchuan and Hou, Yayi and Cao, Peng and Ji, Jianjian},
  title = {Both chebulagic acid and punicalagin inhibit respiratory syncytial virus entry via multi-targeting glycoprotein and fusion protein},
  journal = {Journal of Virology},
  year = {2024},
  doi = {10.1128/jvi.01536-24}
}
Kostenlos starten →